LivaNova (NASDAQ:LIVN) Price Target Raised to $81.00 at Needham & Company LLC

LivaNova (NASDAQ:LIVN) had its price target hoisted by Needham & Company LLC from $64.00 to $81.00 in a research report report published on Wednesday, Marketbeat.com reports. Needham & Company LLC currently has a buy rating on the stock.

A number of other equities research analysts have also recently weighed in on LIVN. KeyCorp assumed coverage on LivaNova in a report on Friday, December 19th. They issued an “overweight” rating and a $81.00 price target on the stock. Robert W. Baird set a $75.00 target price on LivaNova in a report on Tuesday, December 16th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $66.00 price target on shares of LivaNova in a research note on Friday, January 9th. Stifel Nicolaus boosted their price objective on shares of LivaNova from $65.00 to $70.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Finally, Barclays increased their price objective on shares of LivaNova from $58.00 to $67.00 and gave the company an “equal weight” rating in a research note on Friday, January 9th. Seven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $74.11.

LivaNova Stock Performance

NASDAQ:LIVN opened at $70.29 on Wednesday. The firm’s fifty day simple moving average is $64.41 and its 200-day simple moving average is $58.81. The company has a quick ratio of 1.12, a current ratio of 1.33 and a debt-to-equity ratio of 0.30. The stock has a market cap of $3.84 billion, a PE ratio of -17.57 and a beta of 0.97. LivaNova has a fifty-two week low of $32.48 and a fifty-two week high of $70.78.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, February 25th. The company reported $0.86 EPS for the quarter, beating the consensus estimate of $0.80 by $0.06. LivaNova had a negative net margin of 16.12% and a positive return on equity of 15.98%. The firm had revenue of $360.86 million during the quarter, compared to analysts’ expectations of $354.31 million. During the same quarter last year, the business earned $0.81 earnings per share. The business’s revenue for the quarter was up 12.2% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. Analysts expect that LivaNova will post 2.85 earnings per share for the current fiscal year.

Institutional Trading of LivaNova

Large investors have recently made changes to their positions in the stock. Pacer Advisors Inc. raised its stake in LivaNova by 131.7% in the 4th quarter. Pacer Advisors Inc. now owns 16,661 shares of the company’s stock valued at $1,025,000 after purchasing an additional 9,471 shares during the last quarter. Invesco Ltd. grew its holdings in shares of LivaNova by 4.5% during the fourth quarter. Invesco Ltd. now owns 1,091,086 shares of the company’s stock worth $67,135,000 after buying an additional 47,323 shares in the last quarter. Corient Private Wealth LLC acquired a new position in shares of LivaNova in the fourth quarter valued at approximately $604,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of LivaNova during the fourth quarter valued at approximately $306,000. Finally, State of Tennessee Department of Treasury lifted its stake in shares of LivaNova by 44.9% during the fourth quarter. State of Tennessee Department of Treasury now owns 30,304 shares of the company’s stock valued at $1,991,000 after buying an additional 9,396 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Key Headlines Impacting LivaNova

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: Q4 results beat on both revenue and adjusted EPS; revenue was ~$360.9M (up ~12% y/y) and adjusted EPS topped consensus — management issued FY‑2026 adjusted EPS guidance of $4.15–$4.25, above Street estimates, which is the main near-term catalyst. Read More.
• Positive Sentiment: Analyst upgrade/price-target lift: Needham raised its price target to $81 and reiterated a Buy rating, reinforcing bullish sentiment following the results and guidance. Read More.
• Positive Sentiment: Short interest declined materially in February (down ~16.6% to ~2.03M shares), lowering potential downward pressure from short squeezes and signaling reduced bearish positioning into the earnings update.
• Neutral Sentiment: Management materials and the full earnings call transcript are available for deeper read-throughs (useful for assessing margin drivers and product/service momentum). Read More. · Read More.
• Neutral Sentiment: Market commentary is starting to assess longer-term drivers such as reimbursement gains and a new data partnership (Orrum) that could reshape cardiac-care positioning; these are potential catalysts but currently speculative. Read More. · Read More.
• Negative Sentiment: GAAP metrics and margins still show weaknesses: reported GAAP diluted EPS was lower than adjusted EPS and the company reported a negative net margin (~‑16%), suggesting non‑operating items or charges and that underlying profitability still needs improvement. Investors should monitor whether adjusted guidance is supported by sustained operating margin improvement. Read More.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.